A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis

Y Tong; A J Peranteau; Z Nawas; S K Tyring

A Review of Brodalumab, an IL-17 Receptor Antagonist, for Moderate-to-Severe Plaque Psoriasis

Skin Therapy Lett. 2017 Jan;22(1):1-6.

Authors

Y Tong¹, A J Peranteau², Z Nawas³, S K Tyring³

Affiliations

¹ Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, University of California San Diego, La Jolla, CA, USA.
² Center for Clinical Studies, Houston, TX, USA.
³ Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, Houston, TX, USA.

PMID: 28122092

Abstract

Psoriasis is a chronic immune-mediated inflammatory disease with epidermal hyperplasia that affects 2-3% of the population. Interleukin (IL)-17 signaling has a central role in its pathogenesis. Brodalumab is a monoclonal antibody that neutralizes IL-17 receptor type A. Brodalumab is highly effective in the reversal of psoriatic phenotype and gene expression patterns.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Dermatologic Agents / therapeutic use*
Humans
Interleukin-17 / physiology
Psoriasis / drug therapy*
Psoriasis / physiopathology
Receptors, Interleukin-17 / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Dermatologic Agents
Interleukin-17
Receptors, Interleukin-17
brodalumab